Leila Nicolas

Leila Nicolas is a Partner and Investment Director at GO Capital, a technology-focused venture firm founded in 2003 that has become a leading early-stage investor in western France. She leads healthcare and life-sciences investing for the fund, drawing on a combined scientific and business background. She joined GO Capital at the end of 2013 and has since spent more than a decade financing and sitting on the boards of biotech and medtech companies.

Her education blends science and management: a Master's degree in Cell Biology and Neuroscience from the University of Bordeaux II, a Master's in Healthcare Business Management from IAE Lille, and a Finance certificate from ICN (Nancy). Before venture capital, she worked in pharmaceutical and biotech operating roles — as a Product Manager at Bayer Schering Pharma (multiple sclerosis and oncology, from around 2004) and as a Strategic Marketing Manager at the Alsace-based biotech Polyplus-transfection, where she negotiated licensing agreements. She also helped set up a company that developed and sold environmental-health analysis kits before moving into investing.

At GO Capital she is part of the firm's front-office investment team (which the firm currently lists under "Partners"), and she is regularly cited by aggregators such as Crunchbase, Bloomberg and NFX Signal under the "Investment Director" title. GO Capital manages seed and venture funds totaling more than €200M and has financed over 100 innovative companies, investing a large share of its capital in healthcare. Nicolas is a recurring public voice on biotech investing in France, appearing in trade press (Biotech Finances) and podcasts (Equity 101) to discuss how early-stage biotech financing works.

• Invests at seed to Series A in science-heavy healthcare companies — biotech, medtech, diagnostics, pharma, and digital health.
• Ticket sizes roughly €300K–€5M (reinvestments included), with a reported sweet spot near €1.5M.
• Backs companies primarily in France, aligned with GO Capital's "Grand Ouest" (western France) deep-tech, digital and healthtech mandate, plus a national impact-maritime thesis at the fund level.
• Looks for genuine scientific/clinical differentiation and a credible path from lab science to commercialization — reflecting her operating background in pharma marketing, licensing and diagnostics.
• Takes an active, hands-on role: she typically joins portfolio-company boards and supports companies through multiple financing rounds and international expansion.